Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex Corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
10.15
2008
Addex Parkinson’s Product Progressing in Early Clinical Trials
09.26
2008
GSK Reports Owning 3% of Addex
09.10
2008
Better Tolerated Formulation of ADX10059 Reduces Acid Reflux
08.07
2008
Disclosure of Shareholdings in Accordance with Stock Market Rules
08.05
2008
Disclosure of Shareholdings in Accordance with Stock Market Rules
07.28
2008
Addex Pharmaceuticals Reports First Half 2008 Financial Results, Maiden Profit
07.28
2008
Laurent Galibert Appointed Head of Inflammation Business Unit
07.18
2008
Addex First Half 2008 Financial Results Monday, July 28
06.04
2008
Addex Starts Phase I ADX10059 Interaction Study
05.27
2008
Disclosure of Shareholdings in Accordance with Stock Market Rules
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back